Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Amortizatization of Intangibles (2022 - 2025)

InMed Pharmaceuticals (INM) has 4 years of Amortizatization of Intangibles data on record, last reported at $104818.0 in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 38.14% year-over-year to $104818.0; the TTM value through Dec 2025 reached $363904.0, changed 0.09%, while the annual FY2025 figure was $321885.0, 16.38% down from the prior year.
  • Amortizatization of Intangibles reached $104818.0 in Q4 2025 per INM's latest filing, up from $103478.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $104818.0 in Q4 2025 and bottomed at $75876.0 in Q4 2024.
  • Average Amortizatization of Intangibles over 4 years is $93489.1, with a median of $95813.0 recorded in 2023.
  • The widest YoY moves for Amortizatization of Intangibles: up 38.14% in 2025, down 22.88% in 2025.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $98307.0 in 2022, then dropped by 5.31% to $93085.0 in 2023, then decreased by 18.49% to $75876.0 in 2024, then skyrocketed by 38.14% to $104818.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $104818.0 in Q4 2025, $103478.0 in Q3 2025, and $78330.0 in Q2 2025.